Lv71
4990 积分 2021-05-18 加入
Tissue-resident T cells in Clinical Response and Immune-related Adverse Events of Immune Checkpoint Blockade
2小时前
已完结
PP01.93 RET fusion as a treatable resistance mechanism in EGFR mutation lung cancer - A case report
1个月前
已关闭
EP.12A.10 Multi-Omics Uncovers Signatures Associated with Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients
1个月前
已关闭
Tumor-Infiltrating CD103+ Tissue-Resident Memory T Cells and CD103−CD8+ T Cells in HNSCC Are Linked to Outcome in Primary but not Metastatic Disease
4个月前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
6个月前
已完结
Retrospective Review of Outcomes After Radiation Therapy for Oligoprogressive Disease on Immune Checkpoint Blockade
6个月前
已完结
Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective Trials
6个月前
已完结
Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer
6个月前
已完结
Lung Resection After Initial Nonoperative Treatment for Non-Small Cell Lung Cancer
6个月前
已完结
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
6个月前
已完结
皖公网安备34019202002308
